TWI924629B - 經口投予用依達拉奉(Edaravone)懸浮劑 - Google Patents

經口投予用依達拉奉(Edaravone)懸浮劑

Info

Publication number
TWI924629B
TWI924629B TW108139797A TW108139797A TWI924629B TW I924629 B TWI924629 B TW I924629B TW 108139797 A TW108139797 A TW 108139797A TW 108139797 A TW108139797 A TW 108139797A TW I924629 B TWI924629 B TW I924629B
Authority
TW
Taiwan
Prior art keywords
edaravone
suspension
suspending agent
particles
dispersant
Prior art date
Application number
TW108139797A
Other languages
English (en)
Chinese (zh)
Other versions
TW202031256A (zh
Inventor
羽山哲生
高橋朋弘
大村朋幸
林昂司
松田宗智
宮澤忠
Original Assignee
日商田邊製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70463399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI924629(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日商田邊製藥股份有限公司 filed Critical 日商田邊製藥股份有限公司
Publication of TW202031256A publication Critical patent/TW202031256A/zh
Application granted granted Critical
Publication of TWI924629B publication Critical patent/TWI924629B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW108139797A 2018-11-02 2019-11-01 經口投予用依達拉奉(Edaravone)懸浮劑 TWI924629B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-207646 2018-11-02
JP2018207646 2018-11-02

Publications (2)

Publication Number Publication Date
TW202031256A TW202031256A (zh) 2020-09-01
TWI924629B true TWI924629B (zh) 2026-05-11

Family

ID=70463399

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108139797A TWI924629B (zh) 2018-11-02 2019-11-01 經口投予用依達拉奉(Edaravone)懸浮劑

Country Status (20)

Country Link
US (6) US10987341B2 (cg-RX-API-DMAC7.html)
EP (2) EP3875085B1 (cg-RX-API-DMAC7.html)
JP (3) JP7274502B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210087490A (cg-RX-API-DMAC7.html)
CN (4) CN117379369A (cg-RX-API-DMAC7.html)
AR (1) AR116967A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019369843A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008197A2 (cg-RX-API-DMAC7.html)
DK (1) DK3875085T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991523T3 (cg-RX-API-DMAC7.html)
FI (1) FI3875085T3 (cg-RX-API-DMAC7.html)
HU (1) HUE068117T2 (cg-RX-API-DMAC7.html)
IL (2) IL319280A (cg-RX-API-DMAC7.html)
MX (3) MX2021005144A (cg-RX-API-DMAC7.html)
PH (1) PH12021550988A1 (cg-RX-API-DMAC7.html)
PL (1) PL3875085T3 (cg-RX-API-DMAC7.html)
PT (1) PT3875085T (cg-RX-API-DMAC7.html)
SG (1) SG11202104365QA (cg-RX-API-DMAC7.html)
TW (1) TWI924629B (cg-RX-API-DMAC7.html)
WO (1) WO2020091036A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019167178A1 (ja) * 2018-02-28 2019-09-06 田辺三菱製薬株式会社 3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬を含む薬剤の製造方法
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
IN201921028874A (cg-RX-API-DMAC7.html) * 2019-07-18 2021-01-22
JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2020-11-12 2022-05-19
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same
GB202103807D0 (en) 2021-03-18 2021-05-05 Johnson Matthey Plc A crystalline salt of edaravone, processes for the preparation and use thereof
EP4473965A4 (en) 2022-02-03 2026-01-07 Mitsubishi Tanabe Pharma Corp MEDICAL AGENT FOR THE TREATMENT OR SUPPRESSION OF THE PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
WO2024005187A1 (ja) 2022-07-01 2024-01-04 田辺三菱製薬株式会社 組成物、およびエダラボンの応答可能性の評価方法
WO2024172852A1 (en) 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone
CN118178328A (zh) * 2024-03-21 2024-06-14 药云(西安)医药技术有限公司 依达拉奉包埋物制备方法与其口服制剂
US20260130849A1 (en) * 2024-11-13 2026-05-14 Tulex Pharmaceuticals, Inc. Edaravone Oral Solution Compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1129463A (ja) * 1997-05-14 1999-02-02 Senju Pharmaceut Co Ltd 再分散性の良い水性懸濁液剤
JP2004091441A (ja) * 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
WO2018133957A1 (en) * 2017-01-17 2018-07-26 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH07121861B2 (ja) 1986-11-25 1995-12-25 三菱化学株式会社 3−メチル−1−フエニル−2−ピラゾロン−5−オンを含有する安定な注射剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
JPH1120463A (ja) 1997-06-30 1999-01-26 Zexel Corp 車両用デュアルエアコン
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
EP1714960B1 (en) 2004-02-09 2018-03-28 Mitsubishi Tanabe Pharma Corporation Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als
JP5836004B2 (ja) 2010-08-12 2015-12-24 日新化成株式会社 可溶化剤
CN102824356A (zh) 2012-09-25 2012-12-19 江西中医学院 一种黄芩苷纳晶混悬剂、纳晶干粉及其制备方法
US9642843B2 (en) 2013-02-27 2017-05-09 The Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
JP6336246B2 (ja) * 2013-03-13 2018-06-06 大同化成工業株式会社 ナノ粒子化製剤及びその製造方法
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
CN107205935A (zh) 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体
EP3427724A4 (en) 2016-03-10 2019-11-13 Sumitomo Dainippon Pharma Co., Ltd. COMPOSITION WITH FINE PARTICLES AND METHOD FOR THE MANUFACTURE THEREOF
CN109125261B (zh) * 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
EP3785703A1 (en) 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
KR20200024868A (ko) * 2017-07-06 2020-03-09 트리웨이 티더블유001 비.브이. 산화성 스트레스-매개 신경퇴행성 질환의 경구 치료에 사용하기 위한 에다라본의 용도
BR112021008197A2 (pt) * 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
IN201921028874A (cg-RX-API-DMAC7.html) * 2019-07-18 2021-01-22

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1129463A (ja) * 1997-05-14 1999-02-02 Senju Pharmaceut Co Ltd 再分散性の良い水性懸濁液剤
JP2004091441A (ja) * 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
WO2018133957A1 (en) * 2017-01-17 2018-07-26 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Ankit Parikh, et al. " Development of a novel oral delivery system of edaravone for enhancing bioavailability." Int J Pharm. 515(1-2): 2016 Dec 30; 490-500. *

Also Published As

Publication number Publication date
US20240226064A1 (en) 2024-07-11
PT3875085T (pt) 2024-08-09
BR112021008197A2 (pt) 2021-08-03
EP4420724A3 (en) 2024-11-27
PH12021550988A1 (en) 2021-10-04
MX2021005144A (es) 2021-07-15
JP2026010001A (ja) 2026-01-21
HUE068117T2 (hu) 2024-12-28
US11957660B2 (en) 2024-04-16
US11478450B2 (en) 2022-10-25
IL282773A (en) 2021-06-30
KR20210087490A (ko) 2021-07-12
PL3875085T3 (pl) 2024-10-21
WO2020091036A1 (ja) 2020-05-07
EP3875085A1 (en) 2021-09-08
US11241416B2 (en) 2022-02-08
CN112969459A (zh) 2021-06-15
EP4420724A2 (en) 2024-08-28
EP3875085B1 (en) 2024-06-19
JP7828317B2 (ja) 2026-03-11
DK3875085T3 (da) 2024-07-08
CN112969459B (zh) 2023-12-05
US20220110915A1 (en) 2022-04-14
US20200268712A1 (en) 2020-08-27
AU2019369843A1 (en) 2021-05-27
CN117379369A (zh) 2024-01-12
IL282773B1 (en) 2025-04-01
JP2023087011A (ja) 2023-06-22
US10987341B2 (en) 2021-04-27
SG11202104365QA (en) 2021-05-28
CN117398346A (zh) 2024-01-16
JP7274502B2 (ja) 2023-05-16
CN117379370A (zh) 2024-01-12
US12599586B2 (en) 2026-04-14
MX2024000663A (es) 2024-01-31
JPWO2020091036A1 (ja) 2021-09-24
MX2023009973A (es) 2023-09-06
US20210212990A1 (en) 2021-07-15
FI3875085T3 (fi) 2024-08-06
EP3875085A4 (en) 2022-07-27
IL319280A (en) 2025-04-01
TW202031256A (zh) 2020-09-01
AR116967A1 (es) 2021-06-30
US20260232635A1 (en) 2026-08-13
AU2025205635A1 (en) 2025-08-07
AU2019369843A2 (en) 2023-02-02
US20230030285A1 (en) 2023-02-02
ES2991523T3 (es) 2024-12-03
IL282773B2 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
JP7828317B2 (ja) 経口投与用エダラボン懸濁剤
US8263652B2 (en) Stabilized pediatric suspension of carisbamate
US20250235430A1 (en) Edaravone suspension for oral administration
CN108366956B (zh) 物理和化学稳定的吉维诺司他口服混悬液
EP3669879A1 (fr) Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoïque comprenant de la diosmine, et de la gomme xanthane
RU2810789C2 (ru) Суспензия эдаравона для перорального введения
HK40113279A (en) Edaravone suspension for oral administration
HK40053006A (en) Edaravone suspension for oral administration
WO2026028170A1 (en) Pharmaceutical composition of edaravone
HK40053006B (en) Edaravone suspension for oral administration
BR122024020124A2 (pt) Suspensão de edaravone para administração oral, kit para a preparação da mesma, agente terapêutico para a ela, e seus usos